Neutrophil to lymphocyte ratio and risk of neoplastic progression in patients with Barrett's esophagus

被引:11
|
作者
Peleg, Noam [1 ,2 ]
Schmilovitz-Weiss, Hemda [1 ,2 ]
Shamah, Steven [1 ,2 ]
Schwartz, Ariel [3 ]
Dotan, Iris [1 ,2 ]
Sapoznikov, Boris [1 ,2 ]
机构
[1] Rabin Med Ctr, Div Gastroenterol, Petah Tiqwa, Israel
[2] Tel Aviv Univ, Sackler Fac Med, Tel Aviv, Israel
[3] Rabin Med Ctr, Dept Pathol, Petah Tiqwa, Israel
关键词
DIAGNOSIS; MANAGEMENT; CANCER; GUIDELINES; DYSPLASIA; SURVIVAL;
D O I
10.1055/a-1292-8747
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Patient's with Barrett's esophagus (BE) are at risk of progression to esophageal adenocarcinoma (EAC). Neutrophil to lymphocyte ratio (NLR) was found to be a predictor of poor prognosis in patients with EAC; however, its performance in premalignant esophageal lesions is vague. We aimed to evaluate the utility of NLR as a predictor of histologic progression in patients with BE. Methods A prospective cohort of patients with proven BE in a tertiary referral center was retrospectively analyzed. All biopsies were reviewed by an expert gastrointestinal pathologist. The discriminatory capacity of NLR was evaluated by area under the receiver operating characteristic (AUC) curve analysis and Cox regression analysis. Results 324 patients (mean age 62.3 years, 241 [74.4%] males) were included in the final analysis. Overall, 13 patients demonstrated histologic progression to neoplasia over a mean follow-up of 3.7 years (progression risk 1.0% per year). The AUC of NLR for progression to high grade dysplasia (HGD) or EAC was 0.88 (95% confidence interval [CI] 0.83-0.96), and baseline NLR was associated with a 3-fold increase of progression to HGD and EAC during follow-up (hazard ratio [HR] 3.2, 95%CI 1.5-5.8; P <0.001). Notably, in a subgroup analysis of patients with nondysplastic BE (NDBE) at presentation, NLR was also a risk factor for histologic progression (HR 2.4, 95%CI 1.7-3.4; P <0.001). Conclusion NLR predicted histologic progression in patients with BE. Patients with NDBE and NLR above 2.4 can be considered for specific surveillance programs with shorter intervals between sessions.
引用
收藏
页码:774 / 781
页数:8
相关论文
共 50 条
  • [1] Proton Pump Inhibitors Reduce the Risk of Neoplastic Progression in Patients With Barrett's Esophagus
    Kastelein, Florine
    Spaander, Manon C. W.
    Steyerberg, Ewout W.
    Biermann, Katharina
    Valkhoff, Vera E.
    Kuipers, Ernst J.
    Bruno, Marco J.
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2013, 11 (04) : 382 - 388
  • [2] Predictors of dysplastic and neoplastic progression of Barrett's esophagus
    Alnasser, Saleh
    Agnihotram, Raman
    Martel, Myriam
    Mayrand, Serge
    Franco, Eduardo
    Ferri, Lorenzo
    CANADIAN JOURNAL OF SURGERY, 2019, 62 (02) : 93 - 99
  • [3] Higher risk of neoplastic progression of Barrett's esophagus in patients with systemic sclerosis
    Anilkumar, Mythri
    Alkhayyat, Motasem
    Grewal, Udhayvir S.
    Sanaka, Madhusudhan R.
    Thota, Prashanthi N.
    GASTROENTEROLOGY REPORT, 2021, 9 (06): : 595 - 596
  • [4] Histological features indicate the risk of progression of patients with Barrett's esophagus
    Chen, Tiane
    Ly, Hong
    Stairs, Douglas B.
    Jackson, Christopher R.
    Chen, Guoli
    PATHOLOGY RESEARCH AND PRACTICE, 2025, 266 : 155812
  • [5] Predictors for Neoplastic Progression in Patients With Barrett's Esophagus: A Prospective Cohort Study
    Sikkema, M.
    Looman, C. W. N.
    Steyerberg, E. W.
    Kerkhof, M.
    Kastelein, F.
    van Dekken, H.
    van Vuuren, A. J.
    Bode, W. A.
    van der Valk, H.
    Ouwendijk, R. J. T.
    Giard, R.
    Lesterhuis, W.
    Heinhuis, R.
    Klinkenberg, E. C.
    Meijer, G. A.
    ter Borg, F.
    Arends, J. W.
    Kolkman, J. J.
    van Baarlen, J.
    de Vries, R. A.
    Mulder, A. H.
    van Tilburg, A. J. P.
    Offerhaus, G. J. A.
    ten Kate, F. J. W.
    Kusters, J. G.
    Kuipers, E. J.
    Siersema, P. D.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 (07) : 1231 - 1238
  • [6] External validation of a model determining risk of neoplastic progression of Barrett's esophagus in a cohort of US veterans
    Nguyen, Theresa H.
    Thrift, Aaron P.
    Ketwaroo, Gyanprakash A.
    Du, Xianglin L.
    Novelo, Luis Leon
    George, Rollin
    Rosen, Daniel G.
    El-Serag, Hashem B.
    GASTROINTESTINAL ENDOSCOPY, 2022, 95 (06) : 1113 - 1122
  • [7] The use of imaging and biomarkers in diagnosing Barrett's esophagus and predicting the risk of neoplastic progression
    Ramzan, Zeeshan
    Nassri, Ammar B.
    Huerta, Sergio
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2014, 14 (05) : 575 - 591
  • [8] Natural selection in neoplastic progression of Barrett's esophagus
    Maley, CC
    Reid, BJ
    SEMINARS IN CANCER BIOLOGY, 2005, 15 (06) : 474 - 483
  • [9] Risk of progression of Barrett's esophagus in patients with cirrhosis
    Apfel, Tehilla
    Lopez, Rocio
    Sanaka, Madhusudhan R.
    Thota, Prashanthi N.
    WORLD JOURNAL OF GASTROENTEROLOGY, 2017, 23 (18) : 3287 - 3294
  • [10] Risk of progression of Barrett's esophagus in patients with cirrhosis
    Tehilla Apfel
    Rocio Lopez
    Madhusudhan R Sanaka
    Prashanthi N Thota
    World Journal of Gastroenterology, 2017, (18) : 3287 - 3294